Club drugs: reasons for and consequences of use.
This preliminary descriptive study was designed to assess the reasons, primary contexts, and consequences (physical, psychological, lifestyle) of club drug use in a sample of young adults in a mid-size U.S. city. Fifty young adults (18 to 30 years old) reported on their use of club drugs (Ecstasy, GHB, ketamine, Rohypnol, methamphetamine, LSD) in face-to-face interviews that included quantitative and qualitative measures. Ecstasy was the most frequently used club drug followed by ketamine, LSD and methamphetamine. All of the participants reported using club drugs to "experiment" and most reported using these drugs to feel good and enhance social activities. Club drugs were frequently used at raves, in bars or clubs, and at home with friends. An average of 16 negative physical, psychological, and lifestyle consequences were reported for club drug use. Despite substantial negative consequences, participants perceived several positive consequences of regular recreational club drug use. These findings corroborate descriptions of club drug use in other countries (e.g., Australia, United Kingdom) and provide additional information on perceived positive consequences that users experience with club drug use. Further exploration of the reasons and positive consequences that are associated with use of each of the club drugs may provide important information on the growing trend in use of these drugs.
Parks
Kathleen A
KA
Research Institute on Addictions, 1021 Main Street, Buffalo, New York 14203, USA. parks@ria.buffalo.edu
Kennedy
Cheryl L
CL
D000293:Adolescent; D000328:Adult; D000697:Central Nervous System Stimulants / Q000009:adverse effects; D003915:Dextromethorphan / Q000009:adverse effects; D005260:Female; D005445:Flunitrazepam / Q000009:adverse effects; D006213:Hallucinogens / Q000009:adverse effects; D006801:Humans; D013287:Illicit Drugs / Q000009:adverse effects*; D007407:Interviews as Topic; D007649:Ketamine / Q000009:adverse effects; D008019:Life Style; D008238:Lysergic Acid Diethylamide / Q000009:adverse effects; D008297:Male; D008694:Methamphetamine / Q000009:adverse effects; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects; D012978:Sodium Oxybate / Q000009:adverse effects; D019966:Substance-Related Disorders / Q000523:psychology*; D014481:United States
D000697:Central Nervous System Stimulants; D006213:Hallucinogens; D013287:Illicit Drugs; D008694:Methamphetamine; D005445:Flunitrazepam; D007649:Ketamine; D003915:Dextromethorphan; D012978:Sodium Oxybate; D008238:Lysergic Acid Diethylamide; D018817:N-Methyl-3,4-methylenedioxyamphetamine